Corline Biomedical (Q3 Initial take): Fairly low sales, as expected - Redeye
Bildkälla: Stockfoto

Corline Biomedical (Q3 Initial take): Fairly low sales, as expected - Redeye

Redeye provides an initial take following the release of Corline's Q3 2026 report. Sales came in below our estimate, but this was largely expected following the company's recently released forecast for 2026, which already signalled a softer quarter. We therefore do not place too much weight on the deviation, as we expect it to be caught up in Q4. Overall, the report contained no major surprises, and we expect to make only minor fine-tuning of our estimates in the research update that we will publish shortly.

Redeye provides an initial take following the release of Corline's Q3 2026 report. Sales came in below our estimate, but this was largely expected following the company's recently released forecast for 2026, which already signalled a softer quarter. We therefore do not place too much weight on the deviation, as we expect it to be caught up in Q4. Overall, the report contained no major surprises, and we expect to make only minor fine-tuning of our estimates in the research update that we will publish shortly.
Börsvärldens nyhetsbrev